Prot #DT2216-001: A Phase 1, Open-Label, Dose Escalation, And Cohort Expansion Study To Evaluate The Safety, Tolerability, Pharmacokinetics (PK) And Clinical Activity Of DT2216, An Antiapoptotic Protein Targeted Degradation Compound, In Subjects With Rela

Project: Research project

Project Details

StatusActive
Effective start/end date1/5/22 → 1/5/25

Funding

  • SCRI Development Innovations, LLC (Prot #DT2216-001)
  • Dialectic Therapeutics, Inc. (Prot #DT2216-001)